Clinical Trials Browser

Phase 1/2 × Metastatic Gastroesophageal Junction Adenocarcinoma × sintilimab × Clear all

NCT06329973 2025-07-17

Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer

Phase 1/2 Recruiting

Gastrointestinal

Metastatic Gastroesophageal Junction Adenocarcinoma